|
|||||
|
|
A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice |
|
| Authors: | Milaid Granadillo Maribel G. VallespiAileen Batte Osmany MendozaYordanka Soria Victoria M. LugoIsis Torrens |
| Affiliation: | a Department of Cancer, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacan, Playa, Havana 10600, Cuba b Animal Care Unit, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacan, Playa, Havana 10600, Cuba c Technological Development Unit, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacan, Playa, Havana 10600, Cuba |
| Abstract: | The ultimate success of cancer vaccination is dependent upon the generation of tumor-specific CTLs. In this study, we designed and evaluated a novel fusion protein comprising a cell penetrating and immunostimulatory peptide corresponding to residues 32-51 of the Limulus polyphemus protein (LALF32-51) linked to human papillomavirus (HPV) 16 E7 antigen (LALF32-51-E7). We demonstrated that LALF32-51 penetrates the cell membrane and delivers E7 into cells. In a preclinical model of HPV16-induced cervical carcinoma we showed that vaccination with adjuvant-free LALF32-51-E7 fusion protein significantly improves the presentation of E7-derived peptides to T-cells in vitro and induces suppression of tumor growth. |
| Keywords: | Fusion protein E7 CPP LALF32-51 |
| 本文献已被 ScienceDirect 等数据库收录！ | |